Within the osteoarthritis therapeutics segmentation, the application dimension partitions the market into three primary uses: pain management, disease modification, and joint‑replacement support. Pain‑management therapies, encompassing oral NSAIDs, topical analgesics, and intra‑articular corticosteroids, dominate the landscape, accounting for roughly 55 % of total sales. Their prevalence reflects the immediate clinical need to alleviate symptomatic discomfort and maintain functional capacity, driving the largest share of R&D spend and reimbursement allocations. Disease‑modifying agents—principally hyaluronic‑acid viscosupplements, biologic disease‑modifying osteoarthritis drugs (DMOADs), and emerging gene‑therapy platforms—represent about 30 % of the market. These products aim to slow cartilage degeneration and alter disease trajectory, attracting premium pricing and longer‑term procurement contracts. The remaining 15 % is allocated to joint‑replacement support, which includes peri‑operative analgesics, bone‑growth stimulators, and postoperative rehabilitation adjuncts that facilitate prosthetic integration. Together, these application categories shape the overall market size by aligning product pipelines with distinct clinical pathways and payer expectations. Consequently, shifts in clinical guidelines or reimbursement policies within any of these applications can materially re‑balance the market composition.
